Top news of the day from across the health care landscape.
This approval expands tezacaftor/ivacaftor’s indication to include patients ages 6 and older with cystic fibrosis who have certain genetic mutations.
Patients with multiple sclerosis who switched disease-modifying treatments at least twice had a higher relative risk of developing cancer.
Officials with the FDA have approved Allergan’s supplemental biologics application (sBLA) for onabotulinumtoxinA (Botox) for the treatment of children, ages 2 to 17 years, with upper limb spasticity.
Top news of the day from across the health care landscape.
Top news of the week from Specialty Pharmacy Times.
2019 Pharmacy Quality Alliance Annual Meeting included discussions on measures to improve medication services and how pharmacists can play a larger role in the multidisciplinary care team.
Company Profile >
Industry Guide >
Market News >
Peer Exchange >
Conferences >
Subscribe >
Specialty Times Resources
About Us
Contact Us
Terms & Conditions
MJH Associates >
Pharmacy Times
American Journal of Managed Care
MD Magazine
Targeted Oncology
Physicians' Education Resource
Pharmacy & Healthcare Communications, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright Specialty Pharmacy Times 2006-2019
Pharmacy & Healthcare Communications, LLC. All Rights Reserved.